BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Glumetinib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Glumetinib\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06525350-2222@assetmemo.bio
DTSTAMP:20261121T005452Z
DTSTART;VALUE=DATE:20261225
DTEND;VALUE=DATE:20261226
SUMMARY:Glumetinib: Phase 2 readout est. (NCT06525350)
DESCRIPTION:Glumetinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A St
 udy to Evaluate the Efficacy and Safety of the Combination of Glumetinib a
 nd Docetaxel（Albumin Bound）Verse Docetaxel for the Treatment of MET-ov
 erexpressed Non-small Cell Lung Cancer\nEstimated primary completion: 25 D
 ecember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/glumeti
 nib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 06525350
URL:https://assetmemo.bio/drug/glumetinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06829459-2222@assetmemo.bio
DTSTAMP:20261121T005452Z
DTSTART;VALUE=DATE:20280215
DTEND;VALUE=DATE:20280216
SUMMARY:Glumetinib: Phase 3 readout est. (NCT06829459)
DESCRIPTION:Glumetinib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A St
 udy to Evaluate the Efficacy and Safety of Glumetinib Combined With Osimer
 tinib Mesylate Versus Platinum-based Doublet Chemotherapy in Non-Small Cel
 l Lung Cancer Patients After Resistance to EGFR-TKIs\nEstimated primary co
 mpletion: 15 February 2028. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/glumetinib#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06829459
URL:https://assetmemo.bio/drug/glumetinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06980532-2222@assetmemo.bio
DTSTAMP:20261121T005452Z
DTSTART;VALUE=DATE:20281230
DTEND;VALUE=DATE:20281231
SUMMARY:Glumetinib: Phase 1/2 readout est. (NCT06980532)
DESCRIPTION:Glumetinib\, phase 1/2.\nStudy: Glumetinib Combined With Fruqui
 ntinib in the Treatment of MET Amplification or Protein Overexpression in 
 Third-Line Unresectable Metastatic Colorectal Cancer\nEstimated primary co
 mpletion: 30 December 2028. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/glumetinib#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06980532
URL:https://assetmemo.bio/drug/glumetinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06908772-2222@assetmemo.bio
DTSTAMP:20261121T005452Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Glumetinib: Phase 2/3 readout est. (NCT06908772)
DESCRIPTION:Glumetinib\, phase 2/3\, Non-Small Cell Lung Cancer.\nStudy: Gl
 umetinib Combined With Osimertinib Treatment for Non-Small Cell Lung Cance
 r Patients\nEstimated primary completion: 31 December 2028. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/glumetinib#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06908772
URL:https://assetmemo.bio/drug/glumetinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
